Stefan van den Eijnde
Director/Board Member at Dutch Vaccines Group
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Domenico Valerio | M | 67 |
University of Leiden
| 32 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frans Ramaekers | M | - |
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | 13 years |
| Nico Vandervelpen | M | 49 |
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | - |
| Thessa Mooij | F | - |
University of Leiden
| 6 years |
| Robertus Lindner | M | 60 |
University of Leiden
| 2 years |
| Jaap Koopman | M | - |
University of Leiden
| 3 years |
| Harry Aaldenberg | M | - |
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | 5 years |
| Kris Motmans | M | - |
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | - |
| Jan van den Brand | M | - |
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | - |
| Markus S. Meijer | M | - |
University of Leiden
| 3 years |
| Mark Sanor | M | - |
University of Leiden
| - |
| Adriaan Stoop | M | 54 |
University of Leiden
| 3 years |
| Robert van Zwieten | M | 62 |
University of Leiden
| 11 years |
| Maarten Kraan | M | 63 |
University of Leiden
| 7 years |
| Mariëlle L. J. Paul | F | 57 |
University of Leiden
| 6 years |
| Jie Weng | M | 61 |
University of Leiden
| 3 years |
| Henk Tissing | M | - |
University of Leiden
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Netherlands | 17 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stefan van den Eijnde
- Personal Network
